CNBC
13 Jun 2026, 12:00 UTC · 13w ago
Verdict
Headline takes no side. We score LLY +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Eli Lilly's experimental triple-acting drug retatrutide demonstrated average weight loss of 28% in Phase 3 trials, with nearly half of patients losing over 30%.
More positive than 98% of claims this week
Novo Nordisk reported that prescriptions for its oral Wegovy pill reached over 3 million within the first five months of launch.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
New competitors including Pfizer, Amgen, and Zealand Pharma are developing long-acting (monthly/quarterly) or low-side-effect alternatives to current weekly GLP-1s.
More positive than 76% of claims this week
Drugmakers are facing pricing pressures and competition from compounding pharmacies, leading to price cuts for weight-loss shots.
So whatDownward pressure on pricing and the rise of cheaper knockoffs can compress margins for the primary patent holders.
More negative than 81% of claims this week
Structure Therapeutics and AstraZeneca are developing small-molecule GLP-1 pills targeted for market entry around 2029.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Dominating the market with impressive data from its experimental drug retatrutide and strong presence in oral pills.
More positive than 80% of ticker scores this week
Strong performance of its Wegovy pill with over 3 million prescriptions in five months.
More positive than 74% of ticker scores this week
Unveiled promising mid-stage data for a monthly injection gained through acquisition.
More positive than 74% of ticker scores this week
Testing a potentially more convenient monthly or quarterly obesity treatment.
More positive than 68% of ticker scores this week
Shared positive mid-stage data from its GLP-1 pill trials.
More positive than 68% of ticker scores this week
Shared positive mid-stage data for its GLP-1 pill and expressed optimism about market positioning.
More positive than 68% of ticker scores this week
Presented mid-stage data for petrelintide showing weight loss and favorable side-effect profiles.
More positive than 63% of ticker scores this week
Co-developing a new amylin-based obesity drug with Zealand Pharma.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1d ago
More positive than 96% of relationship scores this week
[mutual] Both are market leaders in GLP-1 obesity drugs and compete on pricing and product launches.
More positive than 57% of relationship scores this week
[mutual] Zealand Pharma is developing the drug petrelintide in partnership with Roche.
More positive than 35% of relationship scores this week
[mutual] AstraZeneca is developing GLP-1 pills to enter the market currently led by Eli Lilly.
More positive than 35% of relationship scores this week
[mutual] Amgen is testing obesity drugs to compete with current weekly injection leaders like Eli Lilly.
More positive than 35% of relationship scores this week
[mutual] Structure Therapeutics is developing a small molecule pill to compete with Lilly's Foundayo.
More positive than 35% of relationship scores this week
[mutual] Zealand Pharma is developing amylin drugs while Eli Lilly is developing its own amylin analogue.
+1.2%
Price agrees with the score
$1146.04 vs $1133.00 close before publication (Jun 12) · not market-adjusted
LLY chart →
